No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership
AC Immune Announces Promising Safety Data for Down Syndrome Therapy
Express News | AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients
AC Immune Reports Interim Safety Data From Phase 1b/2 ABATE Trial of ACI-24.060 in Down Syndrome
AC Immune Q3 2024: Strong Progress and Financial Turnaround
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)